Health ProductsAdvisory

Archived – Health Canada Determines Viracept (nelfinavir mesylate) Can Be Used Again In Non-Pregnant HIV-Infected Adults and Children

· Published by Health Canada · Official notice

Details

Alert type: Advisory
Category: Drugs, Affects children, pregnant or breast feeding women
Issue: Product Safety, Important Safety Information, Poisoning Hazard
Audience: General Public, Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

Following up on a Public Communication issued September 10, 2007, Health Canada wishes to inform Canadians and Canadian health care professionals that Health Canada and Pfizer Canada have agreed on an acceptable ethyl methanesulfonate limit for Viracept, a drug used in the treatment of HIV/AIDS. Health Canada would like to assure Canadians that the Viracept product now available on the Canadian market has the acceptable ethyl methanesulfonate limits so that the precautions relating to its use in non-pregnant HIV infected adults and children no longer apply.

Health Canada would also like to remind Canadians of its advice against the use of Viracept in pregnant women due to safety concerns regarding ethyl methanesulfonate during pregnancy.

In September 2007, Health Canada was made aware of international findings of low levels of a toxic impurity in Viracept. As a result, Pfizer Canada, in collaboration with Health Canada, advised health care professionals to switch pregnant women and children using Viracept to other available HIV/AIDS medications as soon as possible.

At that time, in consultation with Health Canada, Pfizer Canada immediately began working to limit the levels of ethyl methanesulfonate formed in Viracept during the manufacturing process. The U.S. FDA also requires the same acceptable ethyl methanesulfonate limits for Viracept on their market.

Health Canada continues to work with Pfizer Canada to ensure the Viracept product on the Canadian market does not exceed the acceptable ethyl methanesulfonate limit. Canadians will continue to be informed if new safety information arises.

For more information on the VIRACEPT Dear Health Care Professional Letter, and/or the VIRACEPT Public Communication, please visit the Healthy Canadians Web site.

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime